Pfizer Receivables 2010-2024 | PFE
Pfizer receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
- Pfizer receivables for the quarter ending September 30, 2024 were $14.451B, a 30.35% increase year-over-year.
- Pfizer receivables for 2023 were $11.177B, a 2.05% increase from 2022.
- Pfizer receivables for 2022 were $10.952B, a 4.59% decline from 2021.
- Pfizer receivables for 2021 were $11.479B, a 45.07% increase from 2020.
Pfizer Annual Receivables
(Millions of US $) |
| 2023 |
$11,177 |
| 2022 |
$10,952 |
| 2021 |
$11,479 |
| 2020 |
$7,913 |
| 2019 |
$6,772 |
| 2018 |
$8,025 |
| 2017 |
$8,221 |
| 2016 |
$8,225 |
| 2015 |
$8,176 |
| 2014 |
$8,401 |
| 2013 |
$9,357 |
| 2012 |
$10,675 |
| 2011 |
$13,058 |
| 2010 |
$13,380 |
| 2009 |
$14,645 |
Pfizer Quarterly Receivables
(Millions of US $) |
| 2024-09-30 |
$14,451 |
| 2024-06-30 |
$11,393 |
| 2024-03-31 |
$10,989 |
| 2023-12-31 |
$11,566 |
| 2023-09-30 |
$11,086 |
| 2023-06-30 |
$10,231 |
| 2023-03-31 |
$12,305 |
| 2022-12-31 |
$10,952 |
| 2022-09-30 |
$16,076 |
| 2022-06-30 |
$15,155 |
| 2022-03-31 |
$13,225 |
| 2021-12-31 |
$11,479 |
| 2021-09-30 |
$11,897 |
| 2021-06-30 |
$10,587 |
| 2021-03-31 |
$9,864 |
| 2020-12-31 |
$7,913 |
| 2020-09-30 |
$10,012 |
| 2020-06-30 |
$9,128 |
| 2020-03-31 |
$9,881 |
| 2019-12-31 |
$6,772 |
| 2019-09-30 |
$9,439 |
| 2019-06-30 |
$9,793 |
| 2019-03-31 |
$9,599 |
| 2018-12-31 |
$8,025 |
| 2018-09-30 |
$10,024 |
| 2018-06-30 |
$9,873 |
| 2018-03-31 |
$9,452 |
| 2017-12-31 |
$8,221 |
| 2017-09-30 |
$10,002 |
| 2017-06-30 |
$9,476 |
| 2017-03-31 |
$8,892 |
| 2016-12-31 |
$8,225 |
| 2016-09-30 |
$9,836 |
| 2016-06-30 |
$9,138 |
| 2016-03-31 |
$9,033 |
| 2015-12-31 |
$8,176 |
| 2015-09-30 |
$9,535 |
| 2015-06-30 |
$8,951 |
| 2015-03-31 |
$8,920 |
| 2014-12-31 |
$8,401 |
| 2014-09-30 |
$9,955 |
| 2014-06-30 |
$10,388 |
| 2014-03-31 |
$9,399 |
| 2013-12-31 |
$9,357 |
| 2013-09-30 |
$11,371 |
| 2013-06-30 |
$11,523 |
| 2013-03-31 |
$12,735 |
| 2012-12-31 |
$10,675 |
| 2012-09-30 |
$12,523 |
| 2012-06-30 |
$12,882 |
| 2012-03-31 |
$14,182 |
| 2011-12-31 |
$13,058 |
| 2011-09-30 |
$15,749 |
| 2011-06-30 |
$15,192 |
| 2011-03-31 |
$15,182 |
| 2010-12-31 |
$13,380 |
| 2010-09-30 |
$14,302 |
| 2010-06-30 |
$14,012 |
| 2010-03-31 |
$13,611 |
| 2009-12-31 |
$14,645 |
| 2009-09-30 |
$10,552 |
| 2009-06-30 |
$10,446 |
| 2009-03-31 |
$9,596 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
